Latest Regulatory Process News

NH3 Clean Energy has secured key government approval that streamlines regulatory processes for its WAH2 low-emissions ammonia project, keeping it on track for first production by 2026. This milestone underscores growing state support for decarbonisation initiatives in Western Australia’s strategic industrial zones.

Australian Critical Minerals has completed a strategic acquisition of Circuit Resources, adding six multi-commodity projects in Peru and initiating exploration activities with drilling planned for late 2025.

Netwealth has lodged a formal application for government financial assistance following a $101 million exposure linked to alleged fraud in the First Guardian Master Fund, impacting over a thousand members.

Infinity Metals reports progress on its San Jose lithium mining license application in Spain while facing drilling delays and strategic shifts in its Australian gold-copper projects.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

Resolution Minerals is fast-tracking its downstream antimony strategy in Idaho, aiming to become a key US supplier while preparing for a Nasdaq listing with Tribeca Capital's support.

Island Pharmaceuticals secures FDA confirmation that regulatory feedback on Galidesivir’s approval pathway will arrive on schedule, underscoring the drug’s strategic importance amid US government disruptions.

Sarytogan Graphite Limited has obtained a US$2.2 million loan advance from a related party investor to accelerate its Definitive Feasibility Study on the strategically important Sarytogan Graphite Project in Kazakhstan.

Prominence Energy has extended its agreement to acquire the Gawler Hydrogen Project, allowing more time to secure final regulatory approvals and advance exploration in South Australia.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

NSX Limited shareholders have overwhelmingly approved a scheme of arrangement for acquisition by a CNSX Markets-related entity, setting the stage for a significant market transition pending court approval.